Wall Street analysts expect that Immatics (NASDAQ:IMTX) will report $9.44 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Immatics’ earnings, with estimates ranging from $8.26 million to $10.62 million. The company is scheduled to announce its next earnings report on Wednesday, March 3rd.
On average, analysts expect that Immatics will report full-year sales of $34.85 million for the current year, with estimates ranging from $33.75 million to $36.46 million. For the next year, analysts forecast that the business will post sales of $36.34 million, with estimates ranging from $29.85 million to $44.49 million. Zacks’ sales calculations are an average based on a survey of analysts that cover Immatics.
Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Tuesday, December 1st. The company reported ($2.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($2.56). The business had revenue of $9.22 million during the quarter, compared to the consensus estimate of $9.03 million.
NASDAQ IMTX traded up $0.05 on Thursday, reaching $11.07. 3,265 shares of the company were exchanged, compared to its average volume of 115,822. The business’s fifty day moving average price is $11.07 and its 200 day moving average price is $10.44. Immatics has a fifty-two week low of $8.66 and a fifty-two week high of $17.48.
Large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Immatics in the fourth quarter valued at $83,000. Morgan Stanley purchased a new stake in shares of Immatics in the 3rd quarter valued at $99,000. GWM Advisors LLC purchased a new stake in shares of Immatics in the 3rd quarter valued at $106,000. LPL Financial LLC purchased a new stake in shares of Immatics in the 3rd quarter valued at $115,000. Finally, Granite Point Capital Management L.P. purchased a new stake in shares of Immatics in the 3rd quarter valued at $150,000.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.